FDA WARNING_LETTER - www.mysteroidsmarket.com - July 29, 2025

The FDA issued a warning letter on July 17, 2025, to the operators of the website www.mysteroidsmarket.com, highlighting the unlawful sale of unapproved and misbranded drugs to U.S. consumers over the internet. The inspection revealed that the website was distributing unapproved Schedule II stimulants and benzodiazepines, including amphetamine products marketed as “Buy Adderall Xr 30mg” and “ADDERALL XR®,” as well as benzodiazepines like clonazepam and lorazepam under various brand names. These drugs are considered new drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and lack the necessary FDA approval for interstate commerce, violating sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Act.

The FDA emphasized the public health risks associated with the nonmedical use and diversion of these substances, which are often co-used with other drugs, leading to severe medical outcomes and contributing to overdose deaths. The letter underscores the dangers of purchasing unapproved drugs online, as they may be contaminated, counterfeit, or improperly labeled.

The FDA has mandated that www.mysteroidsmarket.com immediately cease the sale of these unapproved and misbranded drugs to protect U.S. consumers. The agency stresses the importance of compliance with regulatory standards to ensure drug safety and effectiveness.